DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for Zollinger-Ellison Syndrome — screening already-approved drugs against its 3-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleZollinger-Ellison Syndrome maps to a 3-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
approvedOmeprazoleApproved drug
Structures already discussed alongside zollinger-ellison syndrome in the retrieved literature, rendered from public PubChem SMILES. Which drugs appear here reflects the evidence found, not a ranked prediction.
Molecular view
Structure of P450 BM3 A82F F87V — Omeprazole has a real, experimentally solved structure in complex with this target (PDB 4O4P, 1.83 Å). This is the drug's own deposited structure, not a prediction, and confirms it is a structurally characterised molecule rather than an untested guess.
Loading structure…
helix sheet 1c6drag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 4O4P · 1.83 Å · ligand Omeprazole (1C6). Experimental structure, not a prediction.
What the evidence adds up to
In a Northern Irish case series of 16 patients with Zollinger-Ellison syndrome diagnosed between 1970 and 1988, the pattern of management shifted from surgery in the first decade to medical therapy with H2-receptor antagonists or omeprazole in the later period. The authors report that the increasing use of these agents appeared to alter the severe clinical features of the condition, reduce the indications for surgery, and maintain patients—including those with metastatic disease—in clinical remission. No response rates, survival figures, or sample sizes beyond the total of 16 are given in that abstract.
A 2000 review notes that Zollinger-Ellison syndrome occurs sporadically in about 75% of cases and is associated with multiple endocrine neoplasia type 1 (MEN-1) in the remainder. It states that proton pump inhibitors can usually control complications from acid hypersecretion, but that treatment of the direct effects of the gastrinoma itself requires surgical resection. The review explicitly states that the role of surgery remains controversial.
A 1990 article on Losec (omeprazole) describes the drug as a well-tolerated alternative for Zollinger-Ellison syndrome patients, allowing a more natural lifestyle, and also mentions potential benefits for severe gastroesophageal reflux disease when traditional therapy is inadequate. No quantitative efficacy data, survival outcomes, or comparative trial results are provided in that abstract.
What is still missing are prospective randomised trials comparing medical therapy alone against surgical resection, long-term survival data stratified by the presence or absence of MEN-1, and studies that define which patients benefit from surgery despite effective acid suppression. The evidence base remains limited to small case series and expert opinion, with no large, controlled data to settle the controversy over surgical management.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
QJM · 1991 · 10 citations
Changing Patterns in Presentation and Management of the Zollinger-Ellison Syndrome in Northern Ireland, 1970–1988
AbstractThe clinical features, diagnostic methods, management and survival in 16 cases of Zollinger-Ellison syndrome encountered in Northern Ireland between the years 1970 and 1988 are described. While the majority of patients in the first decade of the study period had surgical treatment, those presenting in the latter period have been managed with medical therapy in the form of H2-receptor antagonists or omeprazole. The increasing use of these agents seems to be altering the severe clinical features of this condition, reducing the indications for surgery and maintaining patients, with or without evidence of metastatic disease, in clinical remission.
The American Journal of Gastroenterology · 2000 · 2 citations
Is surgery useful for Zollinger-Ellison syndrome?
AbstractThe Zollinger-Ellison syndrome is an uncommon disorder that occurs sporadically about 75% of the time and is associated with multiple endocrine neoplasia type 1 (MEN-1) in the remainder. Complications from the disease are related to acid hypersecretion or as a direct effect of the gastrinoma itself. Proton pump inhibitors can usually control the former whereas treatment of the latter requires surgical resection. The role of surgery, however, remains controversial.
AbstractThe treatment of patients with Zollinger-Ellison syndrome has represented a challenge in the past. Losec Delayed-Release Capsules may provide these patients with a well-tolerated alternative, allowing them a more natural lifestyle. In addition, Losec may also offer benefits to the patient suffering from severe gastroesophageal reflux disease in whom traditional therapy is not providing adequate results. Knowledge of this newer medication and its advantages and disadvantages will allow the nurse to take an active role in patient instruction regarding this therapy.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
